CURESPONSE

Know. Before.

Company Overview

Curesponse is a clinical/commercial stage start up, maker of the cResponse, an AI-driven, functional/genomics drug prioritization platform that accurately selects the most effective cancer treatment for each patient. The platform combines rapid next generation sequencing (NGS) with a proprietary functional response assay that assesses the response of a patient's cancerous tissue to various drug and drug combinations, while preserving functional Tumor Microenvironment (TME). This combination enables cResponse to be the only platform that can offer patients, oncologists, and pharma partners a truly empirical test that captures the sensitivity and resistance of an individual tumor to 10 different drugs/drug combinations within 2 weeks from biopsy/surgery, across the full therapeutic modality spectrum (chemo, biologics, IO).



The vision driving the design of the platform is rooted in the understanding that for a personalized drug selection test to be widely adopted, it will need to deliver consistently actionable results across all solid tumours, treatment lines, and across the full spectrum to cancer treatment modalities (including I/O, Chemo and Targeted Therapy) and it will need to do all that in an agile, scalable manner that accommodates a new drug in months, not years. This is particularly important due the fact that Genomic-Driven oncology benefit less than 10% of patients with cancers that harbor certain easily identifiable genetic mutations,

Business Summary

The cResponse test is CE marked under IVDD and is routinely reimbursed by private payers in Israel and Clalit, the largest HMO in Israel, 2nd largest HMO in the world. The test will be offered to UK and EU cancer patients in H2 23, and to USA patients in 2024. In addition to the clinical service, the company is collaborating with leading pharma partners, offering a less expensive and more timely drug discovery and development platform. Commercial test revenues are led by lung, breast, ovarian, sarcoma, pancreas, and colorectal cancer.

Opportunity

Metastatic cancer patients exceed 2,000,000 in the US, EU, and Japan. Accordingly, the total accessible market in these markets exceeds $12B. In the USA, Curesponse' main market target, metastatic cancer patients represent a $4B opportunity and the global pharma services market is estimated to be $2B. An additional market which will follow the metastatic cancer segment are Neo-Adjuvant cancer patients, which represent an $2.4B USA market.

www.curesponse.com | Guy Neev | Guy@curesponse.tech | +972 54 8006200

Management Team

Guy Neev | CEO & Co-founder
Guy@curesponse.tech

Gil Rosen | COO
Gil@curesponse.tech

Prof. Ravid Straussman |
Scientific Founder

Dr Vered Bar | VP R&D

Dr Seth Salpete | CTO & Co-founder

Prof. Raanan Berger | CMO

Zvika Slovin | Chair of the BOD

Solution

Using IP licensed from world renowned Straussman lab at the Weitzman Institute, the cResponse™ platform evaluates tumor sensitivity to cancer drugs by preserving the cancer tissue – including the tumor microenvironment (with vasculature and immune system) to reflect the closest possible model to cancer growth found in the body. Our proprietary assay enables the patient's 3 dimensional tissue sample to remain viable in our lab for a period of time sufficient to allow genomic assessment and capture the empirical response to the patient' next line drug candidates. Using proprietary protocols the platform treats the tissues samples in a method mimicking the expected clinical outcome. A Machine Learning algorithm is used to quantify the drug-related damage caused to the malignant cells within the Tumor Microenvironment.

Recently submitted study (presented at AACR and currently under peer review) of the assay performance in bladder, pancreas and additional solid tumors showed a sensitivity of 97%, and specificity > 85% in response assessment. Calibrating the platform for a new drug is routinely accomplished in < 3 months, and test results are delivered to patients and their oncology team in 2 weeks from biopsy.

Curesponse currently operates 2 labs: In Israel and inLondon. A USA lab is planned for late 2023.

Go To Market Strategy

Throughout its rapid growth, the platform is already generating 2 revenue channels: a commercial test for oncologists and their patients as well as Discovery & pre-clinical services for pharma partners. The platform will be introduced in the USA under CLIA as an LDT in 2024. The company will be executing a USA based rigorous post market study that will support favourable payers' coverage decisions by demonstrating the pharmacoeconomic as well as the clinical value of a highly actionable, empirical, cancer agnostic personalized drug selection test. Data from the study will be used towards FDA approval should the company decide to further enhance its regulatory position.